In terms of Cyrus hosting a call just to reassure us that
In terms of Cyrus hosting a call just to reassure us that things are ok in the wake of departing employees, I just can't see them wasting their time. Since the Nadering occurred they haven't seemed to care too much about sharing information. Or the daily share price. This sounds like quite a bit of presentation building just to try to "hide" the news of Ray and possibly Recknor leaving.
I'm of the opinion this will be somewhere in between a deeper dive into plans for the three main indications (Nash, Oncology, HIV) and an announcement of some sort of grant/funding or partnership. I can't imagine we'll get a real big story with this being during trading hours, but I also can't imagine they'd host this with nothing new to add. The first doesn't seem likely because of general trading regulations, and the second doesn't seem likely because they've gone out of their way to lay low and disseminate information only when necessary or when they truly have something to say. But there's nothing stopping them from releasing a premarket PR with some major news and then discussing it further in the call. I wouldn't bet on that though.
Lastly, I don't think it's about a buyout for a variety of reasons. But mainly because that's going to require a vote, time to consider the offer, and a better understanding of where we stand with LL's development today. In fact, maybe this update call is the first step in the buyout process we get to see publicly. We get the update informing us of how we should currently be valuing LL, then a buyout offer is announced and we're in a better position to accept it because it aligns with what our management team just explained. Many of us have numbers in our head that are ultimately way too high. If that perception was righted through a call like this, maybe a no vote turns into a yes vote for a much smaller, but ultimately fair number. I don't know. I still don't think it's about a buyout.
If I had to bet, I'd say it's finally nearing time for whatever our next phase is going to be (partner, going it alone, whatever) and this is when they share the blueprint with us before breaking ground and building a muthatrucking dynasty up in this bitch.
#muthatruckingdynasty #upinthisbitch
16
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...
Continue Reading
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
Top 5 Most Recently Viewed Articles
HCW Biologics Unveils Innovative Treatments for Solid Tumors HCW Biologics Inc., a clinical-stage biopharmaceutical company, recently announced important developments in its research on second-generation, multi-specific T-cell engagers. These therapies specifically target solid tumors, notably pancreatic cancer, utilizing the company's proprietary TRBC product discovery...
Continue Reading
Overview of the Small Cap Growth Virtual Investor Conference The Small Cap Growth Virtual Investor Conference is set to take place soon, bringing together a diverse group of companies and investors. This exciting virtual event will provide a platform for companies to showcase their offerings to interested investors from various backgrounds. The conference promises an...
Continue Reading
Introduction to Crexi Auction's 2025 Performance As the landscape of commercial real estate evolves, Crexi Auction stands out with remarkable performance metrics indicating a strong rebound in market confidence. Recent reports highlight a 96% close rate for Crexi Auction during the first half of the year, showcasing a notable 10% year-over-year increase in transaction...
Continue Reading
Digihost and NANO Nuclear Join Forces for Renewable Energy Digihost Technology Inc. and NANO Nuclear Energy Inc. have united to submit a proposal to the New York State Energy Research and Development Authority (NYSERDA). Their aim? To facilitate the development of cutting-edge, clean energy solutions that will revolutionize New York's energy landscape. This collaboration...
Continue Reading
Syndax Pharmaceuticals (NASDAQ: SNDX) and Its Market Journey Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) has recently made headlines as its stock price has fallen to a 52-week low of $12.75. This decline is indicative of the current hurdles the biopharmaceutical company is facing in a challenging market landscape. Investors have noted that the stock is currently in an...
Continue Reading